Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells by Sander, S. & Rajewsky, K.
Oncotarget 2012; 3: 1066-10671066www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, October, Vol.3, No 10
Burkitt lymphomagenesis linked to MYC plus PI3K in germinal 
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Burkitt lymphoma (BL) is a highly aggressive 
germinal center (GC) derived B cell lymphoma. Its 
successful treatment requires intense therapeutic 
protocols that include high doses of alkylating agents 
and central nervous system (CNS) prophylaxis [1]. 
Outcome is still poor in patients over the age of 40 years. 
Thus, less toxic and more targeted treatment strategies 
are needed to improve BL management, especially in 
developing countries, where BL occurs endemically and 
infrastructural shortages preclude appropriate treatment.
A better understanding of BL pathogenesis is a 
prerequisite for therapeutic advance. Activation of the 
MYC proto-oncogene at 8q24 via translocation to one of 
the immunoglobulin loci is typically detected in BL [2]. 
Despite driving proliferation and retarding differentiation, 
sole MYC overexpression is not sufficient for tumor 
development because of its associated apoptotic effects. 
Although many studies have focused on the oncogenic 
potential of MYC deregulation, the pro-survival signals 
co-operating with MYC in BL development remained 
elusive. 
Based on comprehensive transcript analyses in 
human BL, revealing low NF-κB activity, [3,4] and the 
implication of PI3K in mature B cell survival [5], the 
PI3K pathway seemed a good candidate for providing 
the increased survival signal in BL development. We 
indeed found that transgenic mice in which combined 
MYC overexpression and constitutive activation of the 
PI3K pathway was targeted into GC B cells developed 
lymphomas strikingly resembling human BL [6]. The 
tumors in this model displayed not only a GC B cell like 
gene expression pattern, but also phenocopied their human 
counterparts with respect to location, histology, cell 
surface marker expression and other characteristics. Like 
most cases of BL diagnosed in the Western hemisphere, 
the mouse tumors predominantly presented as an 
abdominal mass stemming from the Peyer’s patches. In 
addition, the murine lymphomas showed BL characteristic 
immunohistochemistry (BCL6pos, BCL2neg, Ki67>95%) 
and mRNA profiles (BL gene expression signature).
The most striking demonstration of the GC B 
cell origin of the BL-like tumors arising in the mutant 
mice was that of ongoing somatic hypermutation of the 
rearranged immunoglobulin variable gene segments in the 
tumor cells, as it is also observed in human BL. Former 
mouse models addressing the impact of MYC activation 
in B cell lymphomagenesis but nor targeting the event 
specifically into GC B cells, resulted in the generation 
of lymphomas originating from pre-GC B cells and 
resembling human BL only to limited extents [7-9].
The monoclonality of the tumors arising in mice 
upon MYC and PI3K pathway activation in GC B cells 
implies, that additional, tertiary mutations are needed for 
tumor development. Indeed, the tumors displayed unique 
genomic aberrations including trisomy of chromosome 6, 
which comprises genomic regions commonly gained in 
human BL, and somatic mutations of Ccnd3 [6], a member 
of the D cyclin family essential for GC B cell proliferation. 
Notably, a recent analysis of human BL by transcriptome 
sequencing also reported CCND3 mutations partly 
affecting the same codons as in the mouse tumors [10], 
a finding confirmed by Sander et al. (2012). Furthermore, 
the study by Schmitz and colleagues revealed mutations 
affecting the TCF3/ID3 genes that result in consecutive 
B cell receptor upregulation and thus provide a potential 
mechanism for PI3K activation in human BL, which was 
indeed observed by both Schmitz and Sander et al. (2012). 
In summary, we hypothesized cooperation between 
MYC and PI3K in BL development and functionally 
validated this hypothesis through conditional targeted 
mutagenesis in the mouse. This implicates the PI3K 
pathway in addition to MYC as a therapeutic target in BL. 
Additional therapeutic targets are suggested by tertiary 
mutations recurrently found in the mouse tumors and 
human BL. Ultimately, the in vivo model offers exciting 
opportunities to improve BL treatment by testing novel 
therapeutic strategies in the context of normal physiology, 
including a functional immune system. A particularly 
attractive perspective is the study of mechanisms 
controlling tumor metastasis, like the dissemination of BL 
into the CNS. 
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